Cholesterol is essential for some normal processes. Cholesterol is a structural component of the cell membrane and is a component of some hormones and vitamins and is required for the production of some bile acids. Synthesis occurs in the body, but cholesterol is also found in certain foods. Cholesterol is carried in the blood attached to lipoproteins, of which there are two main types. Low density lipoprotein, LDL, and high density lipoprotein, HDL. LDL is considered the main culprit of coronary artery disease.
Allicor
An article in the Oct. 19, 2010, "Lipids in Health and Disease" showed that taking two Allicor tablets a day reduced LDL cholesterol significantly. They also showed that taking Allicor also had a significant reduction in cardiovascular risk. A further study published by the same researchers in 2009 showed that treatment with Allicor had no side effects.
Lovaza
Lovaza contains high levels of eicosapentaenoic acid, EPA, and docosahexaenoic acid, DHA. The American Heart Association recommends that patients with coronary artery disease should take 1g a day of EPA/DHA. A study reported in the October-December 1997 "Journal of Cardiovascular Risk" showed that the ingredients in Lovaza reduced LDL and with no side effects.
Trilipix
Trilipix is a fenofibric acid and exerts its effect by reducing lipid metabolism. It also reduces cholesterol synthesis and increases cholesterol excretion. Side effects are usually minor even when combined with other drugs such as statins as described in the April 1, 2010, "American Journal of Cardiovascular Drugs."
References
- "Lipids in Health and Disease"; The Effects of Time - Released Garlic Powder Tablets on Multi-Functional; Sobenin IA, et al.; October 2010
- "Journal of Artherosclerosis and Thrombosis"; Lipid-Lowering Effects of Time-Released Garlic Powder Tablets in Double-Blinded Placebo-Contolled Randomised Trial; Sobenin IA et al.; October 2008
- American Heart Association: Fish and Omega 3 Fatty Acids
- "Journal of Cardiovascular Risk"; Safety and Efficacy of Omacor in Severe Hypertriglyceridemia; Harris WS, et al.; October 1997
- "American Journal of Cardiovascular Drugs"; Efficacy and Safety of Fenofibric Acid Co-administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus: Results of a Pooled Subgroup Analysis from Three Randomized, Controlled, Double-Blind Trials;Jones PH, et al.; October 2010
